27)A pharmaceutical firm’s R&D studies show that a new pain medication, while highly effective at reliving pain, places individuals at high risk for a heart attack. Because of the effectiveness of the medication in pain relief，the firm is likely to sell a lot of medication, increasing profits and shareholder value. Despite this, the CEO decides not to market the product due to the health risk to patients. His decision is based on which of the following arguments for CSR?
(A)Moral responsibility
(B)Sustainability
(C)License to operate
(D)Reputation